Jim Greenwood on Data Exclusivity and Healthcare Innovation

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.

Click here for reuse options!
Copyright 2009 Biotechblog

   2 Comments


  1. Mudita Jain
      May 4, 2017

    Hi Jim,

    If the marketing authorisation is withdrawn for a medicinal product, does it still have Data Exclusivity?

Leave a Reply

%d bloggers like this: